Google’s Isomorphic Labs, a division focusing on drug discovery using artificial intelligence, recently raised $600 million in funding led by Thrive Capital. The technology behind Isomorphic Labs was developed by DeepMind, a central intelligence lab in London, and includes AlphaFold, which can predict the structure of proteins, DNA, and RNA.
The goal of the company is to revolutionize the drug discovery process by conducting most of it through computers, slashing development time and costs. Isomorphic is currently researching treatments for cancer and immune disorders and has partnerships with major drug makers like Eli Lilly and Novartis.
While Isomorphic did not necessarily need the capital, bringing in outside investors like Thrive will help expand their research models and recruit top talent in various scientific disciplines. Thrive Capital, known for investing in A.I. companies, sees the potential for A.I. to radically change drug discovery and creation.
Isomorphic plans to continue making breakthroughs in computational models like AlphaFold and hopes to have drug candidates ready for preclinical trials in the near future. The company aims to be an independent powerhouse in the industry, with plans to raise more funds from outside investors in the future. With its cutting-edge technology and bold ambitions, Isomorphic Labs is poised to make a significant impact in the world of drug discovery.
Note: The image is for illustrative purposes only and is not the original image of the presented article.
